QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF For Our Patients Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nelson, M. H Articles by Dolder, C. R Search for Related Content PubMed PubMed Citation Articles by Nelson, M. H Articles by Dolder, C. R

NEW DRUG DEVELOPMENTS

Lapatinib: A Novel Dual Tyrosine Kinase Inhibitor with Activity in Solid Tumors

Associate Professor of Pharmacy, School of Pharmacy, Wingate University, Wingate, NC

Christian R Dolder, PharmD BCPS

Assistant Professor of Pharmacy, School of Pharmacy, Wingate University; Pharmacist, North-East Medical Center, Concord, NC

Reprints: Dr. Nelson, School of Pharmacy, Wingate University, Campus Box 3087, Wingate, NC 28174-0159, fax 704/233-8332, mnelson{at}wingate.edu

OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical trials, adverse effects, and drug interactions of lapatinib.

DATA SOURCES: A PubMed search was conducted (1966-August 2005) using the following terms: lapatinib, GW572016, and dual tyrosine kinase inhibitor. Additional information sources included meeting abstracts, clinical trial data, and bibliographies from articles identified through PubMed.

STUDY SELECTION AND DATA EXTRACTION: Preclinical and clinical trials that evaluated lapatinib in cell culture, animal models, and human subjects were selected from the data sources. Pivotal in vitro data and all in vivo data published regarding lapatinib were included.

DATA SYNTHESIS: The development of tyrosine kinase inhibitors has resulted from a search for targeted cancer therapeutics made possible by recent gains in our understanding of tumor cell biology. Lapatinib is a dual tyrosine kinase inhibitor selective for inhibition of epidermal growth factor receptor and human epidermal growth factor receptor-2 autophosphorylation, leading to suppression of proliferation pathways of solid tumors. Lapatinib has shown clinical activity in solid tumors, with the most notable in advanced or metastatic breast cancer, including tumors refractory to trastuzumab. It has a mild adverse effect profile, with the most common adverse events being diarrhea and rash.

CONCLUSIONS: Lapatinib has novel, dual tyrosine kinase inhibitory properties selective for factors overexpressed in some solid tumors. Results from preclinical and Phase I/II trials indicate activity in the treatment of solid tumors, especially advanced or metastatic breast cancer. Application for approval is anticipated pending results of ongoing Phase III trials.

Key Words: breast cancer, dual tyrosine kinase inhibitor, EGFR, GW572016, HER2, lapatinib

Published Online, January 17, 2006. www.theannals.com, DOI 10.1345/aph.1G387

This article has been cited by other articles:

				K. J. Harrington, I. A. El-Hariry, C. S. Holford, A. Lusinchi, C. M. Nutting, D. Rosine, M. Tanay, E. Deutsch, J. Matthews, C. D'Ambrosio, et al. Phase I Study of Lapatinib in Combination With Chemoradiation in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck J. Clin. Oncol., March 1, 2009; 27(7): 1100 - 1107. [Abstract] [Full Text] [PDF]

				U. B. McGovern, R. E. Francis, B. Peck, S. K. Guest, J. Wang, S. S. Myatt, J. Krol, J. M-M. Kwok, A. Polychronis, R. C. Coombes, et al. Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer Mol. Cancer Ther., March 1, 2009; 8(3): 582 - 591. [Abstract] [Full Text] [PDF]

				A. P. Martin, A. Miller, L. Emad, M. Rahmani, T. Walker, C. Mitchell, M. P. Hagan, M. A. Park, A. Yacoub, P. B. Fisher, et al. Lapatinib Resistance in HCT116 Cells Is Mediated by Elevated MCL-1 Expression and Decreased BAK Activation and Not by ERBB Receptor Kinase Mutation Mol. Pharmacol., September 1, 2008; 74(3): 807 - 822. [Abstract] [Full Text] [PDF]

				J. Krol, R. E. Francis, A. Albergaria, A. Sunters, A. Polychronis, R. C. Coombes, and E. W.-F. Lam The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells Mol. Cancer Ther., December 1, 2007; 6(12): 3169 - 3179. [Abstract] [Full Text] [PDF]

				D. Tripathy Capecitabine in Combination with Novel Targeted Agents in the Management of Metastatic Breast Cancer: Underlying Rationale and Results of Clinical Trials Oncologist, April 1, 2007; 12(4): 375 - 389. [Abstract] [Full Text] [PDF]

				J. T. Jorgensen, K. V. Nielsen, and B. Ejlertsen Pharmacodiagnostics and Targeted Therapies--A Rational Approach for Individualizing Medical Anticancer Therapy in Breast Cancer Oncologist, April 1, 2007; 12(4): 397 - 405. [Abstract] [Full Text] [PDF]

				R. R. Patel and M. P. Mehta Targeted Therapy for Brain Metastases: Improving the Therapeutic Ratio Clin. Cancer Res., March 15, 2007; 13(6): 1675 - 1683. [Abstract] [Full Text] [PDF]

				N. Steeghs, J. W. R. Nortier, and H. Gelderblom Small Molecule Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: An Update of Recent Developments Ann. Surg. Oncol., February 1, 2007; 14(2): 942 - 953. [Abstract] [Full Text] [PDF]

				B. Moy and P. E. Goss Lapatinib: Current Status and Future Directions in Breast Cancer Oncologist, November 1, 2006; 11(10): 1047 - 1057. [Abstract] [Full Text] [PDF]